Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Says Anti-C5 mAb Shuts Down Complement Activity

publication date: Jun 17, 2022

CANbridge (HK:1228), a Beijing-Cambridge MA rare disease/rare oncology company, reported promising results from a Phase I trial of its long-acting anti-C5 mAb. The C5 protein is a component of the complement system. Dysregulation or over-activity of the complement pathway is implicated in diseases that include paroxysmal nocturnal hemoglobinuria. In the trial, CAN106 led to rapid, dose-dependent reductions in free C5 and in CH50, a measure of serum hemolytic activity. At the two highest doses, CAN106 achieved a complete blockade of terminal complement activity. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here